Stop COVID Cohort: An Observational Study of 3480 Patients Admitted to the Sechenov University Hospital Network in Moscow City for Suspected Coronavirus Disease 2019 (COVID-19) Infection

Munblit, Daniel; Nekliudov, Nikita A; Bugaeva, Polina; Blyuss, Oleg; Kislova, Maria; Listovskaya, Ekaterina; Gamirova, Aysylu; Shikhaleva, Anastasia; Belyaev, V. E.; Timashev, P. S.; Warner, John O.; Comberiati, Pasquale; Apfelbacher, Christian; Безруков, Е. А.; Политов, М Е; Yavorovskiy, Andrey; Буланова, Е Л; Tsareva, Natalya; Авдеев, С. Н.; Капустина, Валентина; Pigolkin, Yu. I.; Dankwa, Emmanuelle A.; Kartsonaki, Christiana; Pritchard, Mark G; Fоmin, Victоr; Svistunov, Andrey; Butnaru, Denis; Glybochko, Petr

doi:10.1093/cid/ciaa1535

Cited by 57 publications

(47 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of interest, the high mortality risk of elderly adults was consistently observed in China, European regions, and North America ( Figure 2 ). Indeed, similar findings have been consistently reported by single-country studies of COVID-19 patients in many countries such as America [ 12 ], Belgium [ 13 ], Canada [ 14 ], France [ 15 ], Germany [ 16 ], Italy [ 17 ], Mexico [ 18 ], Poland [ 19 ], Romania [ 20 ], Russia [ 21 ], Spain [ 22 ], and the United Kingdom [ 23 ]. Of note, age, gender, and chronic comorbidities are key factors that determine hospitalization rather than outpatient care [ 10 ].…”

Section: Discussionsupporting

confidence: 78%

Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study

Liu

Jing

et al. 2020

Aging

View full text Add to dashboard Cite

The COVID-19 pandemic causes severe morbidity and mortality. This multi-country study aimed to explore risk factors that drive mortality in COVID-19 patients who received neither dexamethasone nor remdesivir. We analyzed a cohort of 568 survivors and 507 non-survivors from China, European regions, and North America. Elderly males ≥70 years accounted for only 25% of survivors, but this rate was significantly higher in non-survivors from China (55%), European regions (63%), and North America (47%). Compared with survivors, non-survivors had more incidences of comorbidities such as cerebrovascular disease and chronic obstructive pulmonary disease (COPD, p-values<0.05). Survival analyses revealed age, male gender, shortness of breath, cerebrovascular disease, and COPD as mortality-associated factors. Survival time from symptom onset was significantly shorter in elderly versus young patients (median: 29 versus 62 days), males versus females (median: 46 versus 59 days), and patients with versus without comorbidities (mean: 41 versus 61 days). Mortality risk was higher in elderly males with comorbidities than in young females without comorbidities (p-value<0.01). Elderly male survivors with comorbidities also had longer hospital stays than other survivors (25 versus 18.5 days, p-value<0.01). Overall, the high mortality risk in elderly males with COVID-19-associated comorbidities supports early prevention and critical care for elderly populations.

show abstract

Section: Discussionsupporting

confidence: 78%

Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study

Liu

Jing

et al. 2020

Aging

View full text Add to dashboard Cite

show abstract

“…The acute phase data were extracted from electronic medical records (EMR) and the Local Health Information System (HIS) at the host institution using the modified and translated ISARIC WHO Clinical Characterisation protocol (CCP) 12 . Details of the acute phase data collection are described elsewhere 3 . The acute-phase dataset included demographics, symptoms, comorbidities, chest computer tomography (CT) reports, supportive care data, and clinical outcomes at discharge.…”

Section: Methodsmentioning

confidence: 99%

Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study

Munblit

Bobkova

Spiridonova

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background The long-term sequalae of COVID-19 remain poorly characterised. In this study, we aimed to assess long-standing symptoms (LS) (symptoms lasting from the time of discharge) in previously hospitalised patients with COVID-19 and assess associated risk factors. Methods This is a longitudinal cohort study of adults (18 years of age and above) with clinically diagnosed or laboratory-confirmed COVID-19 admitted to Sechenov University Hospital Network in Moscow, Russia. Data were collected from patients discharged between April 8 and July 10, 2020. Participants were interviewed via telephone using Tier 1 ISARIC Long-term Follow-up Study CRF and the WHO CRF for Post COVID conditions. Reported symptoms were further categorised based on the system(s) involved. Additional information on dyspnoea, quality of life and fatigue was collected using validated instruments. Multivariable logistic regressions were performed to investigate risk factors for development of LS categories. Findings Overall, 2,649 of 4,755 patients discharged from the hospitals were available for the follow-up and included in the study. The median age of the patients was 56 years (IQR, 46-66) and 1,353 (51.1%) were women. The median follow-up time since hospital discharge was 217.5 (200.4-235.5) days. At the time of the follow-up interview 1247 (47.1%) participants reported LS. Fatigue (21.2%, 551/2599), shortness of breath (14.5%, 378/2614) and forgetfulness (9.1%, 237/2597) were the most common LS reported. Chronic fatigue (25%, 658/2593) and respiratory (17.2% 451/2616) were the most common LS categories. with reporting of multi-system involvement (MSI) less common (11.3%; 299). Female sex was associated with LS categories of chronic fatigue with an odds ratio of 1.67 (95% confidence interval 1.39 to 2.02), neurological (2.03, 1.60 to 2.58), mood and behaviour (1.83, 1.41 to 2.40), dermatological (3.26, 2.36 to 4.57), gastrointestinal (2.50, 1.64 to 3.89), sensory (1.73, 2.06 to 2.89) and respiratory (1.31, 1.06 to 1.62). Pre-existing asthma was associated with neurological (1.95, 1.25 to 2.98) and mood and behavioural changes (2.02, 1.24 to 3.18) and chronic pulmonary disease was associated with chronic fatigue (1.68, 1.21 to 2.32). Interpretation 6 to 8 months after acute infection episode almost a half of patients experience symptoms lasting since hospital discharge. One in ten individuals experiences MSI. Female sex is the main risk factor for majority of the LS categories. chronic pulmonary disease is associated with a higher risk of chronic fatigue development, and asthma with neurological and mood and behaviour changes. Individuals with LS and MSI should be the main target for future research and intervention strategies.

show abstract

“…Investigators from 41 countries are using Research electronic Data Capture (REDCap, version 8.11.11, Vanderbilt University, Nashville, Tenn.) to contribute their data to a central database hosted by the University of Oxford. Additional data were submitted by investigators from Malaysia, Russia [24] and Spain, who were not using the University of Oxford REDCap instance. All investigators retained full rights to their data.…”

Section: Methodsmentioning

confidence: 99%

COVID-19 symptoms at hospital admission vary with age and sex: ISARIC multinational study

Pritchard

2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background Symptom recognition is necessary to identify people with possible Covid-19. Clinical case definitions vary in type and number of symptoms included. No large studies have investigated how these perform for hospitalized patients of different ages and sex. Methods We used international prospective observational data from patients admitted to hospital with laboratory-confirmed Covid-19. We investigated how symptoms varied by age and sex. We performed logistic regression to assess the relationship of age and sex with the most prevalent symptoms in our dataset and with published case definitions, allowing for clustering by country as a random intercept. Results 60,161 patients from 43 countries were included, with median age 70 years (interquartile range 55 - 82). Fever (68%), cough (68%) and shortness of breath (63%) were the most prevalent symptoms. Their prevalence was greater among patients aged 30 - 60 years (respectively 79%, 78%, 66%), and lower in children (≤18 years: 68%, 47%, 22%) and older adults (≥70 years: 61%, 62%, 61%). The most sensitive case definition assessed was one or more of cough, shortness of breath, fever, muscle pains or sore throat, met by 92% of the whole cohort. Confusion was the most prevalent symptom for patients whose symptoms did not meet any of the assessed case definitions. Regression models showed significant differences in symptoms with age, and considerable heterogeneity between countries. Conclusions Older adults and children admitted to hospital with Covid-19 are less likely to present with typical symptoms of cough, fever and shortness of breath. Vigilance for atypical symptoms towards extremities of age increases sensitivity of identifying Covid-19.

show abstract

Stop COVID Cohort: An Observational Study of 3480 Patients Admitted to the Sechenov University Hospital Network in Moscow City for Suspected Coronavirus Disease 2019 (COVID-19) Infection

Cited by 57 publications

References 22 publications

Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study

Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study

Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study

COVID-19 symptoms at hospital admission vary with age and sex: ISARIC multinational study

Contact Info

Product

Resources

About